Clinical Trial Update: A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 safety and efficacy study of ELND002 in relapsing forms of multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ELND002

Snippet

Sponsor: Elan Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 1 | Status: TERMINATED